產品名稱：Oxaliplatin 產品貨號：LC O-7111 產品規(guī)格：1 MG Oxaliplatin is a a third-generation, diaminocyclohexane-containing platinum anti-cancer drug. It is typically used in combination with fluorouracil (5-FU) and leucovorin, known as FOLFOX, for the treatment of colorectal cancer. The leucovorin-modulated single-agent 5-FU regimens achieved a median overall survival of 15 months or less. Combination regimens of FOLFOX consistently lead to median survivals in the 15 to 20-month range. Goldberg, R.M. "Therapy for Metastatic Colorectal Cancer." The Oncologist 11: 981-987 (2006). Oxaliplatin has different antitumor spectrum, mechanisms of action, and resistance from the other platinum-containing compounds, notably cisplatin. Raymond, E., et al. "Cellular and molecular pharmacology of oxaliplatin." Mol. Cancer Ther. 1: 227-235 (2002). The anticancer activity and the antitumor specificity of oxaliplatin mainly depend on human organic cation transporters (OCT) 1 and OCT2. Zhang, S., et al. "Organic cation transporters are determinants of oxaliplatin cytotoxicity." Cancer Res. 66: 8847-8857 (2006). The oxaliplatin cytotoxicity depends on MKK7/JNK, while SEK1 might be involved in hypoxic resistance to oxaliplatin. Vasilevskaya, I.A., et al. "Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin." Mol. Pharmacol. 74: 246-254 (2008). Oxaliplatin is the active ingredient in the drug sold under the trade name Eloxatin®. This drug has been approved in at least one country for use in patients with colorectal cancer. NOTE: The oxaliplatin sold by LC Laboratories is NOT Eloxatin®, and is NOT for human use. Storage: Store at or below -20 ºC. Solubility: Soluble in water at 4 mg/mL and DMSO at 20 mg/mL; very slightly soluble in methanol; insoluble in ethanol. Disposal: A
滬公網安備 31011002002623號
